➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
McKesson
McKinsey
Boehringer Ingelheim
Moodys

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

INSPRA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Inspra patents expire, and when can generic versions of Inspra launch?

Inspra is a drug marketed by Gd Searle Llc and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-two patent family members in twenty-nine countries.

The generic ingredient in INSPRA is eplerenone. There are five drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the eplerenone profile page.

US ANDA Litigation and Generic Entry Outlook for Inspra

A generic version of INSPRA was approved as eplerenone by COREPHARMA on July 30th, 2008.

  Start Trial

Drug patent expirations by year for INSPRA
Drug Prices for INSPRA

See drug prices for INSPRA

Recent Clinical Trials for INSPRA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Malcom Randall VA Medical CenterEarly Phase 1
North Florida Foundation for Research and EducationEarly Phase 1
University of CincinnatiPhase 4

See all INSPRA clinical trials

Pharmacology for INSPRA
Paragraph IV (Patent) Challenges for INSPRA
Tradename Dosage Ingredient NDA Submissiondate
INSPRA TABLET;ORAL eplerenone 021437 2009-06-05
INSPRA TABLET;ORAL eplerenone 021437 2006-09-27

US Patents and Regulatory Information for INSPRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002 AB RX Yes No   Start Trial   Start Trial   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002 DISCN No No   Start Trial   Start Trial   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002 AB RX Yes No   Start Trial   Start Trial   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002 AB RX Yes No   Start Trial   Start Trial   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-002 Sep 27, 2002 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for INSPRA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-002 Sep 27, 2002   Start Trial   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002   Start Trial   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002   Start Trial   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-002 Sep 27, 2002   Start Trial   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002   Start Trial   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for INSPRA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1135139 C01135139/01 Switzerland   Start Trial FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0122232 91072 Luxembourg   Start Trial 91072, EXPIRES: 20090410
0122232 2004C/008 Belgium   Start Trial PRODUCT NAME: EPLERENONE; NATIONAL REGISTRATION NO/DATE: 241 IS 188 F3 20041220; FIRST REGISTRATION: NL RVG 29963 20040316
0122232 300144 Netherlands   Start Trial 300144, 20040410, EXPIRES: 20090409
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
McKesson
McKinsey
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.